Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer

BACKGROUND: Radium-223 is a targeted alpha-particle therapy that improves survival in men with metastatic castration resistant prostate cancer (mCRPC), particularly in men with elevated serum levels of bone alkaline phosphatase (B-ALP). We hypothesized that osteomimicry, a form of epithelial plastic...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, Andrew J., Gupta, Santosh, Healy, Patrick, Kemeny, Gabor, Leith, Beth, Zalutsky, Michael R., Spritzer, Charles, Davies, Catrin, Rothwell, Colin, Ware, Kathryn, Somarelli, Jason A., Wood, Kris, Ribar, Thomas, Giannakakou, Paraskevi, Zhang, Jiaren, Gerber, Drew, Anand, Monika, Foo, Wen-Chi, Halabi, Susan, Gregory, Simon G., George, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538141/
https://www.ncbi.nlm.nih.gov/pubmed/31136607
http://dx.doi.org/10.1371/journal.pone.0216934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538141/
https://www.ncbi.nlm.nih.gov/pubmed/31136607
http://dx.doi.org/10.1371/journal.pone.0216934

Ejemplares similares